Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Clinicopathological features and prognosis of endometrial serous carcinoma
1 Pathology Department, Yantai Yuhuangding Hospital, Yantai, China
2 Central Laboratory, Yantai Yuhuangding Hospital, Yantai, China
3 Oncology Department, Yantai Yuhuangding Hospital, Yantai, China
4 School of Pharmacy, Yantai University, Yantai, China
Eur. J. Gynaecol. Oncol. 2018, 39(1), 53–57; https://doi.org/10.12892/ejgo3553.2018
Published: 10 February 2018
Purpose of investigation: To discuss the clinicopathological features, differential diagnosis, and prognosis of endometrial serous carcinoma (ESC). Materials and Methods: The clinical information of 33 patients aged 44-73 years, admitted to Yantai Huhuangding Hospital for surgical treatment of ESC between January 2003 and December 2013, were retrospectively reviewed. Immunohistochemistry analysis of estrogen (ER), progesterone (PR), and mutant type p53 (MTP53) markers were performed and their correlation with the clinical features and prognosis of ESC were studied. Results: Among all cases, 81.82% were ER- / PR- and 72.73% were MTP53+. Expression of ER, PR, and MTP53 markers were not affected by age, tumor size, infiltration depth, tumor staging or metastasis. P53 mutation might be closely related to the tumorigenesis of ESC and lymphatic metastasis was a predictive factor for poor prognosis. Conclusion : This study provided us a better understanding of this rare type of carcinoma and could benefit future works of gynecologists, oncologists, and pathologists.
Mutant type p53